chartexchange

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

PR Newswire | Oct 23, 2026 7:00 AM EDT

GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors In an HR-proficient ovarian cancer patient-derived...

Read original article